No CrossRef data available.
Article contents
Topiramate for Weighht Loss in Children and Adolescents Prescribed Psychotropic Medications
Published online by Cambridge University Press: 15 April 2020
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Obesity rates in children and adolescents in the United States has tripled since 1980, with 16.9% falling into this range in a 2007-2008 study. Children are increasingly being prescribed antipsychotic medications for a variety of illnesses. This class of medication can lead to increased weight gain, obesity, and metabolic syndrome.
Method
We performed a retrospective chart review in our Child Psychiatry outpatient clinic for visits between 7/1/11 and 6/30/13 looking at the effects of concurrent use of topiramate and antipsychotic medications. Exclusion criteria included concurrent treatment wuth other medications known to cause weight loss (e.g. stimulants), a primary diagnosis of eating disorder, a primary medical illness that would have an impact in weight (e.g. thyroid illness), and medications not prescribed through our clinic.
Brief Results
N = 47 with a mean age of 13.36 years.
Mean dosage for topiramate was 121.74 mg.
Mean baseline BMI = 31.82.
Mean treatment length = 200 days.
Mean weight loss = 0.97 BMI points
Discussion
We will review the United States FDA indications for topiramate, the potential adverse events, and the preliminary data regarding the effectiveness for the treatment of weight gain, for patients prescribed and not prescribed antipsychotic medications.
- Type
- Article: 0694
- Information
- European Psychiatry , Volume 30 , Issue S1: Abstracts of the 23rd European Congress of Psychiatry , March 2015 , pp. 1
- Copyright
- Copyright © European Psychiatric Association 2015
You have
Access
Comments
No Comments have been published for this article.